nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—kidney cancer—testicular cancer	0.32	1	CtDrD
Sorafenib—STK10—testicular cancer	0.253	0.736	CbGaD
Sorafenib—KIT—testicular cancer	0.0906	0.264	CbGaD
Sorafenib—RALBP1—Doxorubicin—testicular cancer	0.0359	0.188	CbGbCtD
Sorafenib—UGT1A1—Etoposide—testicular cancer	0.00908	0.0474	CbGbCtD
Sorafenib—ABCG2—Dactinomycin—testicular cancer	0.00885	0.0462	CbGbCtD
Sorafenib—CYP3A7—Ifosfamide—testicular cancer	0.00771	0.0403	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.00771	0.0403	CbGbCtD
Sorafenib—CYP2B6—Ifosfamide—testicular cancer	0.00735	0.0384	CbGbCtD
Sorafenib—ABCC2—Carboplatin—testicular cancer	0.00658	0.0344	CbGbCtD
Sorafenib—ABCC4—Methotrexate—testicular cancer	0.00613	0.032	CbGbCtD
Sorafenib—ABCC2—Vinblastine—testicular cancer	0.00613	0.032	CbGbCtD
Sorafenib—ABCG2—Carboplatin—testicular cancer	0.00595	0.0311	CbGbCtD
Sorafenib—CYP3A5—Ifosfamide—testicular cancer	0.00579	0.0302	CbGbCtD
Sorafenib—ABCC2—Cisplatin—testicular cancer	0.00562	0.0294	CbGbCtD
Sorafenib—CYP2C8—Ifosfamide—testicular cancer	0.00556	0.0291	CbGbCtD
Sorafenib—ABCC2—Etoposide—testicular cancer	0.00552	0.0288	CbGbCtD
Sorafenib—ABCG2—Cisplatin—testicular cancer	0.00508	0.0265	CbGbCtD
Sorafenib—ABCG2—Etoposide—testicular cancer	0.00499	0.0261	CbGbCtD
Sorafenib—CYP2C19—Ifosfamide—testicular cancer	0.00467	0.0244	CbGbCtD
Sorafenib—CYP2C9—Ifosfamide—testicular cancer	0.00388	0.0203	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—testicular cancer	0.00377	0.0197	CbGbCtD
Sorafenib—ABCC2—Methotrexate—testicular cancer	0.00365	0.0191	CbGbCtD
Sorafenib—CYP2B6—Cisplatin—testicular cancer	0.00357	0.0187	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—testicular cancer	0.0034	0.0178	CbGbCtD
Sorafenib—ABCG2—Methotrexate—testicular cancer	0.0033	0.0172	CbGbCtD
Sorafenib—ABCB1—Dactinomycin—testicular cancer	0.00319	0.0167	CbGbCtD
Sorafenib—CYP3A5—Etoposide—testicular cancer	0.00277	0.0144	CbGbCtD
Sorafenib—CYP2C8—Etoposide—testicular cancer	0.00266	0.0139	CbGbCtD
Sorafenib—CYP2B6—Doxorubicin—testicular cancer	0.00239	0.0125	CbGbCtD
Sorafenib—KIT—seminiferous tubule of testis—testicular cancer	0.00226	0.0557	CbGeAlD
Sorafenib—CYP3A4—Ifosfamide—testicular cancer	0.00226	0.0118	CbGbCtD
Sorafenib—CYP1A2—Etoposide—testicular cancer	0.00206	0.0108	CbGbCtD
Sorafenib—ABCB1—Vinblastine—testicular cancer	0.002	0.0104	CbGbCtD
Sorafenib—CYP2C9—Cisplatin—testicular cancer	0.00189	0.00986	CbGbCtD
Sorafenib—CYP2D6—Vinblastine—testicular cancer	0.00188	0.00983	CbGbCtD
Sorafenib—Regorafenib—KIT—testicular cancer	0.00187	1	CrCbGaD
Sorafenib—ABCB1—Cisplatin—testicular cancer	0.00183	0.00957	CbGbCtD
Sorafenib—ABCB1—Etoposide—testicular cancer	0.0018	0.0094	CbGbCtD
Sorafenib—ABCB1—Doxorubicin—testicular cancer	0.00123	0.00641	CbGbCtD
Sorafenib—CYP3A4—Vinblastine—testicular cancer	0.0012	0.00625	CbGbCtD
Sorafenib—ABCB1—Methotrexate—testicular cancer	0.00119	0.00621	CbGbCtD
Sorafenib—CYP2D6—Doxorubicin—testicular cancer	0.00116	0.00604	CbGbCtD
Sorafenib—CYP3A4—Etoposide—testicular cancer	0.00108	0.00563	CbGbCtD
Sorafenib—CDKL3—gonad—testicular cancer	0.00105	0.0258	CbGeAlD
Sorafenib—CDKL2—gonad—testicular cancer	0.000957	0.0236	CbGeAlD
Sorafenib—MAPK15—gonad—testicular cancer	0.000862	0.0212	CbGeAlD
Sorafenib—MUSK—testis—testicular cancer	0.000846	0.0209	CbGeAlD
Sorafenib—CDKL3—testis—testicular cancer	0.000754	0.0186	CbGeAlD
Sorafenib—CYP3A4—Doxorubicin—testicular cancer	0.000736	0.00384	CbGbCtD
Sorafenib—CDKL2—testis—testicular cancer	0.00069	0.017	CbGeAlD
Sorafenib—MAPK15—testis—testicular cancer	0.000621	0.0153	CbGeAlD
Sorafenib—ZAK—seminal vesicle—testicular cancer	0.000601	0.0148	CbGeAlD
Sorafenib—HIPK4—gonad—testicular cancer	0.00058	0.0143	CbGeAlD
Sorafenib—EPHX2—seminal vesicle—testicular cancer	0.000504	0.0124	CbGeAlD
Sorafenib—AURKC—gonad—testicular cancer	0.000495	0.0122	CbGeAlD
Sorafenib—FLT4—embryo—testicular cancer	0.000484	0.0119	CbGeAlD
Sorafenib—EPHA6—gonad—testicular cancer	0.000458	0.0113	CbGeAlD
Sorafenib—RET—embryo—testicular cancer	0.000427	0.0105	CbGeAlD
Sorafenib—HIPK3—gonad—testicular cancer	0.000425	0.0105	CbGeAlD
Sorafenib—MAP3K7—seminal vesicle—testicular cancer	0.000424	0.0105	CbGeAlD
Sorafenib—HIPK4—testis—testicular cancer	0.000418	0.0103	CbGeAlD
Sorafenib—MAPK11—female gonad—testicular cancer	0.000415	0.0102	CbGeAlD
Sorafenib—MKNK2—seminal vesicle—testicular cancer	0.000411	0.0101	CbGeAlD
Sorafenib—CDK7—female gonad—testicular cancer	0.000409	0.0101	CbGeAlD
Sorafenib—TAOK2—female gonad—testicular cancer	0.000405	0.00999	CbGeAlD
Sorafenib—FLT1—embryo—testicular cancer	0.000376	0.00927	CbGeAlD
Sorafenib—RAF1—embryo—testicular cancer	0.000374	0.00922	CbGeAlD
Sorafenib—RALBP1—seminal vesicle—testicular cancer	0.000372	0.00916	CbGeAlD
Sorafenib—MAPK11—testis—testicular cancer	0.000368	0.00908	CbGeAlD
Sorafenib—CDK7—testis—testicular cancer	0.000362	0.00893	CbGeAlD
Sorafenib—FLT3—gonad—testicular cancer	0.000362	0.00891	CbGeAlD
Sorafenib—TAOK2—testis—testicular cancer	0.00036	0.00886	CbGeAlD
Sorafenib—AURKC—testis—testicular cancer	0.000357	0.00879	CbGeAlD
Sorafenib—FLT1—seminal vesicle—testicular cancer	0.000353	0.00871	CbGeAlD
Sorafenib—ZAK—female gonad—testicular cancer	0.000353	0.0087	CbGeAlD
Sorafenib—PDGFRA—embryo—testicular cancer	0.000353	0.00869	CbGeAlD
Sorafenib—RAF1—seminal vesicle—testicular cancer	0.000351	0.00866	CbGeAlD
Sorafenib—EPHB6—seminal vesicle—testicular cancer	0.000349	0.00861	CbGeAlD
Sorafenib—HIPK3—female gonad—testicular cancer	0.000346	0.00852	CbGeAlD
Sorafenib—EPHA6—testis—testicular cancer	0.00033	0.00814	CbGeAlD
Sorafenib—TIE1—female gonad—testicular cancer	0.000323	0.00796	CbGeAlD
Sorafenib—KDR—embryo—testicular cancer	0.000318	0.00784	CbGeAlD
Sorafenib—ZAK—testis—testicular cancer	0.000313	0.00772	CbGeAlD
Sorafenib—CSF1R—embryo—testicular cancer	0.00031	0.00765	CbGeAlD
Sorafenib—BRAF—female gonad—testicular cancer	0.00031	0.00763	CbGeAlD
Sorafenib—HIPK3—testis—testicular cancer	0.000306	0.00756	CbGeAlD
Sorafenib—MAP3K19—testis—testicular cancer	0.0003	0.0074	CbGeAlD
Sorafenib—MAP2K5—seminal vesicle—testicular cancer	0.000299	0.00736	CbGeAlD
Sorafenib—KDR—seminal vesicle—testicular cancer	0.000299	0.00736	CbGeAlD
Sorafenib—MKNK2—gonad—testicular cancer	0.000297	0.00733	CbGeAlD
Sorafenib—EPHX2—female gonad—testicular cancer	0.000296	0.00729	CbGeAlD
Sorafenib—FLT3—female gonad—testicular cancer	0.000294	0.00724	CbGeAlD
Sorafenib—MKNK1—gonad—testicular cancer	0.000294	0.00724	CbGeAlD
Sorafenib—CSF1R—seminal vesicle—testicular cancer	0.000292	0.00719	CbGeAlD
Sorafenib—TIE1—testis—testicular cancer	0.000286	0.00706	CbGeAlD
Sorafenib—KIT—embryo—testicular cancer	0.000282	0.00695	CbGeAlD
Sorafenib—PDGFRB—embryo—testicular cancer	0.000275	0.00679	CbGeAlD
Sorafenib—BRAF—testis—testicular cancer	0.000275	0.00677	CbGeAlD
Sorafenib—MAPK11—lymph node—testicular cancer	0.000267	0.00658	CbGeAlD
Sorafenib—FLT4—female gonad—testicular cancer	0.000267	0.00658	CbGeAlD
Sorafenib—KIT—seminal vesicle—testicular cancer	0.000265	0.00653	CbGeAlD
Sorafenib—FGFR1—female gonad—testicular cancer	0.000263	0.00649	CbGeAlD
Sorafenib—CDK7—lymph node—testicular cancer	0.000263	0.00648	CbGeAlD
Sorafenib—EPHX2—testis—testicular cancer	0.000262	0.00647	CbGeAlD
Sorafenib—FLT3—testis—testicular cancer	0.000261	0.00642	CbGeAlD
Sorafenib—TAOK2—lymph node—testicular cancer	0.000261	0.00642	CbGeAlD
Sorafenib—AURKC—lymph node—testicular cancer	0.000259	0.00637	CbGeAlD
Sorafenib—PDGFRB—seminal vesicle—testicular cancer	0.000259	0.00637	CbGeAlD
Sorafenib—FLT1—gonad—testicular cancer	0.000255	0.00629	CbGeAlD
Sorafenib—RAF1—gonad—testicular cancer	0.000254	0.00626	CbGeAlD
Sorafenib—MAP3K7—female gonad—testicular cancer	0.000249	0.00614	CbGeAlD
Sorafenib—STK10—gonad—testicular cancer	0.000242	0.00596	CbGeAlD
Sorafenib—MKNK2—female gonad—testicular cancer	0.000242	0.00596	CbGeAlD
Sorafenib—PDGFRA—gonad—testicular cancer	0.000239	0.0059	CbGeAlD
Sorafenib—MKNK1—female gonad—testicular cancer	0.000239	0.00588	CbGeAlD
Sorafenib—FLT4—testis—testicular cancer	0.000237	0.00583	CbGeAlD
Sorafenib—FGFR1—testis—testicular cancer	0.000234	0.00576	CbGeAlD
Sorafenib—ZAK—lymph node—testicular cancer	0.000227	0.0056	CbGeAlD
Sorafenib—HIPK3—lymph node—testicular cancer	0.000222	0.00548	CbGeAlD
Sorafenib—MAP3K7—testis—testicular cancer	0.000221	0.00545	CbGeAlD
Sorafenib—CDK7—Idarubicin—Epirubicin—testicular cancer	0.000221	0.173	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Epirubicin—testicular cancer	0.000221	0.173	CbGdCrCtD
Sorafenib—CDK7—Doxorubicin—Epirubicin—testicular cancer	0.000221	0.173	CbGdCrCtD
Sorafenib—RALBP1—female gonad—testicular cancer	0.000218	0.00538	CbGeAlD
Sorafenib—MKNK2—testis—testicular cancer	0.000214	0.00528	CbGeAlD
Sorafenib—MKNK1—testis—testicular cancer	0.000212	0.00522	CbGeAlD
Sorafenib—CSF1R—gonad—testicular cancer	0.000211	0.00519	CbGeAlD
Sorafenib—RET—testis—testicular cancer	0.000209	0.00515	CbGeAlD
Sorafenib—TIE1—lymph node—testicular cancer	0.000208	0.00512	CbGeAlD
Sorafenib—FLT1—female gonad—testicular cancer	0.000208	0.00512	CbGeAlD
Sorafenib—RAF1—female gonad—testicular cancer	0.000206	0.00509	CbGeAlD
Sorafenib—EPHB6—female gonad—testicular cancer	0.000205	0.00506	CbGeAlD
Sorafenib—CDK7—Epirubicin—Doxorubicin—testicular cancer	0.000204	0.16	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—testicular cancer	0.000204	0.16	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—testicular cancer	0.000204	0.16	CbGdCrCtD
Sorafenib—BRAF—lymph node—testicular cancer	0.000199	0.00491	CbGeAlD
Sorafenib—STK10—female gonad—testicular cancer	0.000196	0.00484	CbGeAlD
Sorafenib—PDGFRA—female gonad—testicular cancer	0.000194	0.00479	CbGeAlD
Sorafenib—RALBP1—testis—testicular cancer	0.000193	0.00477	CbGeAlD
Sorafenib—KIT—gonad—testicular cancer	0.000191	0.00472	CbGeAlD
Sorafenib—EPHX2—lymph node—testicular cancer	0.00019	0.00469	CbGeAlD
Sorafenib—FLT3—lymph node—testicular cancer	0.000189	0.00466	CbGeAlD
Sorafenib—PDGFRB—gonad—testicular cancer	0.000187	0.00461	CbGeAlD
Sorafenib—FLT1—testis—testicular cancer	0.000184	0.00454	CbGeAlD
Sorafenib—RAF1—testis—testicular cancer	0.000183	0.00451	CbGeAlD
Sorafenib—EPHB6—testis—testicular cancer	0.000182	0.00448	CbGeAlD
Sorafenib—KDR—female gonad—testicular cancer	0.000175	0.00432	CbGeAlD
Sorafenib—MAP2K5—female gonad—testicular cancer	0.000175	0.00432	CbGeAlD
Sorafenib—STK10—testis—testicular cancer	0.000174	0.00429	CbGeAlD
Sorafenib—PDGFRA—testis—testicular cancer	0.000172	0.00425	CbGeAlD
Sorafenib—FLT4—lymph node—testicular cancer	0.000172	0.00423	CbGeAlD
Sorafenib—CSF1R—female gonad—testicular cancer	0.000171	0.00422	CbGeAlD
Sorafenib—FGFR1—lymph node—testicular cancer	0.000169	0.00417	CbGeAlD
Sorafenib—MAP3K7—lymph node—testicular cancer	0.00016	0.00395	CbGeAlD
Sorafenib—MAP2K5—testis—testicular cancer	0.000156	0.00384	CbGeAlD
Sorafenib—KDR—testis—testicular cancer	0.000156	0.00384	CbGeAlD
Sorafenib—KIT—female gonad—testicular cancer	0.000155	0.00383	CbGeAlD
Sorafenib—MKNK2—lymph node—testicular cancer	0.000155	0.00383	CbGeAlD
Sorafenib—MKNK1—lymph node—testicular cancer	0.000153	0.00378	CbGeAlD
Sorafenib—CSF1R—testis—testicular cancer	0.000152	0.00374	CbGeAlD
Sorafenib—PDGFRB—female gonad—testicular cancer	0.000152	0.00374	CbGeAlD
Sorafenib—RET—lymph node—testicular cancer	0.000151	0.00373	CbGeAlD
Sorafenib—ABCG2—seminal vesicle—testicular cancer	0.000145	0.00358	CbGeAlD
Sorafenib—RALBP1—lymph node—testicular cancer	0.00014	0.00346	CbGeAlD
Sorafenib—KIT—testis—testicular cancer	0.000138	0.0034	CbGeAlD
Sorafenib—PDGFRB—testis—testicular cancer	0.000135	0.00332	CbGeAlD
Sorafenib—FLT1—lymph node—testicular cancer	0.000133	0.00329	CbGeAlD
Sorafenib—RAF1—lymph node—testicular cancer	0.000133	0.00327	CbGeAlD
Sorafenib—EPHB6—lymph node—testicular cancer	0.000132	0.00325	CbGeAlD
Sorafenib—STK10—lymph node—testicular cancer	0.000126	0.00311	CbGeAlD
Sorafenib—PDGFRA—lymph node—testicular cancer	0.000125	0.00308	CbGeAlD
Sorafenib—ABCC4—female gonad—testicular cancer	0.000121	0.00298	CbGeAlD
Sorafenib—MAP2K5—lymph node—testicular cancer	0.000113	0.00278	CbGeAlD
Sorafenib—KDR—lymph node—testicular cancer	0.000113	0.00278	CbGeAlD
Sorafenib—CSF1R—lymph node—testicular cancer	0.00011	0.00271	CbGeAlD
Sorafenib—ABCC4—testis—testicular cancer	0.000107	0.00264	CbGeAlD
Sorafenib—ABCC2—testis—testicular cancer	0.000104	0.00256	CbGeAlD
Sorafenib—KIT—lymph node—testicular cancer	9.99e-05	0.00246	CbGeAlD
Sorafenib—PDGFRB—lymph node—testicular cancer	9.76e-05	0.00241	CbGeAlD
Sorafenib—CYP2B6—gonad—testicular cancer	9.69e-05	0.00239	CbGeAlD
Sorafenib—ABCG2—female gonad—testicular cancer	8.53e-05	0.0021	CbGeAlD
Sorafenib—CYP3A5—female gonad—testicular cancer	7.92e-05	0.00195	CbGeAlD
Sorafenib—CYP2C8—testis—testicular cancer	7.78e-05	0.00192	CbGeAlD
Sorafenib—ABCC4—lymph node—testicular cancer	7.77e-05	0.00192	CbGeAlD
Sorafenib—HTR2B—lymph node—testicular cancer	7.73e-05	0.00191	CbGeAlD
Sorafenib—ABCB1—embryo—testicular cancer	7.63e-05	0.00188	CbGeAlD
Sorafenib—ABCG2—testis—testicular cancer	7.57e-05	0.00187	CbGeAlD
Sorafenib—ABCC2—lymph node—testicular cancer	7.52e-05	0.00185	CbGeAlD
Sorafenib—ABCB1—seminal vesicle—testicular cancer	7.17e-05	0.00177	CbGeAlD
Sorafenib—CYP2B6—testis—testicular cancer	6.98e-05	0.00172	CbGeAlD
Sorafenib—CYP2D6—female gonad—testicular cancer	5.85e-05	0.00144	CbGeAlD
Sorafenib—ABCG2—lymph node—testicular cancer	5.49e-05	0.00135	CbGeAlD
Sorafenib—CYP2D6—testis—testicular cancer	5.19e-05	0.00128	CbGeAlD
Sorafenib—ABCB1—gonad—testicular cancer	5.18e-05	0.00128	CbGeAlD
Sorafenib—ABCB1—female gonad—testicular cancer	4.21e-05	0.00104	CbGeAlD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	4.06e-05	0.000643	CcSEcCtD
Sorafenib—Decreased appetite—Cisplatin—testicular cancer	4.06e-05	0.000642	CcSEcCtD
Sorafenib—Diarrhoea—Dactinomycin—testicular cancer	4.04e-05	0.00064	CcSEcCtD
Sorafenib—Pneumonia—Methotrexate—testicular cancer	4.04e-05	0.00064	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—testicular cancer	4.04e-05	0.000639	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Cisplatin—testicular cancer	4.03e-05	0.000638	CcSEcCtD
Sorafenib—Vomiting—Bleomycin—testicular cancer	4.03e-05	0.000638	CcSEcCtD
Sorafenib—Infestation NOS—Methotrexate—testicular cancer	4.02e-05	0.000636	CcSEcCtD
Sorafenib—Infestation—Methotrexate—testicular cancer	4.02e-05	0.000636	CcSEcCtD
Sorafenib—Rash—Bleomycin—testicular cancer	3.99e-05	0.000632	CcSEcCtD
Sorafenib—Gastritis—Doxorubicin—testicular cancer	3.99e-05	0.000632	CcSEcCtD
Sorafenib—Pain—Cisplatin—testicular cancer	3.99e-05	0.000632	CcSEcCtD
Sorafenib—Dermatitis—Bleomycin—testicular cancer	3.99e-05	0.000632	CcSEcCtD
Sorafenib—Hypersensitivity—Ifosfamide—testicular cancer	3.99e-05	0.000632	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—testicular cancer	3.98e-05	0.00063	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	3.98e-05	0.00063	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—testicular cancer	3.95e-05	0.000625	CcSEcCtD
Sorafenib—Neutropenia—Epirubicin—testicular cancer	3.94e-05	0.000624	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—testicular cancer	3.91e-05	0.00062	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—testicular cancer	3.9e-05	0.000617	CcSEcCtD
Sorafenib—Asthenia—Ifosfamide—testicular cancer	3.88e-05	0.000615	CcSEcCtD
Sorafenib—Pruritus—Ifosfamide—testicular cancer	3.83e-05	0.000606	CcSEcCtD
Sorafenib—Pancreatitis—Doxorubicin—testicular cancer	3.82e-05	0.000605	CcSEcCtD
Sorafenib—Weight decreased—Epirubicin—testicular cancer	3.81e-05	0.000604	CcSEcCtD
Sorafenib—Dyspnoea—Etoposide—testicular cancer	3.81e-05	0.000604	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—testicular cancer	3.8e-05	0.000601	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—testicular cancer	3.79e-05	0.0006	CcSEcCtD
Sorafenib—Pneumonia—Epirubicin—testicular cancer	3.78e-05	0.000598	CcSEcCtD
Sorafenib—Nausea—Bleomycin—testicular cancer	3.76e-05	0.000596	CcSEcCtD
Sorafenib—Infestation NOS—Epirubicin—testicular cancer	3.76e-05	0.000595	CcSEcCtD
Sorafenib—Infestation—Epirubicin—testicular cancer	3.76e-05	0.000595	CcSEcCtD
Sorafenib—Vomiting—Dactinomycin—testicular cancer	3.76e-05	0.000595	CcSEcCtD
Sorafenib—ABCB1—testis—testicular cancer	3.73e-05	0.00092	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Epirubicin—testicular cancer	3.73e-05	0.00059	CcSEcCtD
Sorafenib—Rash—Dactinomycin—testicular cancer	3.73e-05	0.00059	CcSEcCtD
Sorafenib—Decreased appetite—Etoposide—testicular cancer	3.72e-05	0.000589	CcSEcCtD
Sorafenib—Diarrhoea—Ifosfamide—testicular cancer	3.7e-05	0.000586	CcSEcCtD
Sorafenib—Renal failure—Epirubicin—testicular cancer	3.69e-05	0.000585	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Etoposide—testicular cancer	3.69e-05	0.000584	CcSEcCtD
Sorafenib—Body temperature increased—Cisplatin—testicular cancer	3.69e-05	0.000584	CcSEcCtD
Sorafenib—Fatigue—Etoposide—testicular cancer	3.69e-05	0.000584	CcSEcCtD
Sorafenib—Neuropathy peripheral—Epirubicin—testicular cancer	3.68e-05	0.000583	CcSEcCtD
Sorafenib—Jaundice—Epirubicin—testicular cancer	3.66e-05	0.00058	CcSEcCtD
Sorafenib—Stomatitis—Epirubicin—testicular cancer	3.66e-05	0.00058	CcSEcCtD
Sorafenib—Pain—Etoposide—testicular cancer	3.66e-05	0.000579	CcSEcCtD
Sorafenib—Constipation—Etoposide—testicular cancer	3.66e-05	0.000579	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—testicular cancer	3.65e-05	0.000577	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—testicular cancer	3.62e-05	0.000574	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—testicular cancer	3.61e-05	0.000571	CcSEcCtD
Sorafenib—Dizziness—Ifosfamide—testicular cancer	3.58e-05	0.000567	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—testicular cancer	3.56e-05	0.000564	CcSEcCtD
Sorafenib—Hepatobiliary disease—Epirubicin—testicular cancer	3.55e-05	0.000563	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—testicular cancer	3.55e-05	0.000561	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—testicular cancer	3.53e-05	0.00056	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—testicular cancer	3.53e-05	0.000559	CcSEcCtD
Sorafenib—Nausea—Dactinomycin—testicular cancer	3.51e-05	0.000556	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—testicular cancer	3.5e-05	0.000554	CcSEcCtD
Sorafenib—Gastrointestinal pain—Etoposide—testicular cancer	3.5e-05	0.000554	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—testicular cancer	3.48e-05	0.000551	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—testicular cancer	3.48e-05	0.000551	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	3.45e-05	0.000546	CcSEcCtD
Sorafenib—Vomiting—Ifosfamide—testicular cancer	3.44e-05	0.000545	CcSEcCtD
Sorafenib—Hypersensitivity—Cisplatin—testicular cancer	3.44e-05	0.000544	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—testicular cancer	3.42e-05	0.000541	CcSEcCtD
Sorafenib—Rash—Ifosfamide—testicular cancer	3.41e-05	0.00054	CcSEcCtD
Sorafenib—Dermatitis—Ifosfamide—testicular cancer	3.41e-05	0.00054	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—testicular cancer	3.41e-05	0.00054	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—testicular cancer	3.41e-05	0.00054	CcSEcCtD
Sorafenib—Urticaria—Etoposide—testicular cancer	3.4e-05	0.000538	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—testicular cancer	3.39e-05	0.000537	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—testicular cancer	3.39e-05	0.000537	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—testicular cancer	3.39e-05	0.000537	CcSEcCtD
Sorafenib—Body temperature increased—Etoposide—testicular cancer	3.38e-05	0.000535	CcSEcCtD
Sorafenib—Abdominal pain—Etoposide—testicular cancer	3.38e-05	0.000535	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—testicular cancer	3.37e-05	0.000534	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—testicular cancer	3.36e-05	0.000532	CcSEcCtD
Sorafenib—Asthenia—Cisplatin—testicular cancer	3.35e-05	0.00053	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—testicular cancer	3.35e-05	0.00053	CcSEcCtD
Sorafenib—Urinary tract disorder—Epirubicin—testicular cancer	3.33e-05	0.000527	CcSEcCtD
Sorafenib—Connective tissue disorder—Epirubicin—testicular cancer	3.32e-05	0.000525	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—testicular cancer	3.31e-05	0.000524	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—testicular cancer	3.29e-05	0.000521	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—testicular cancer	3.28e-05	0.000519	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—testicular cancer	3.27e-05	0.000518	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—testicular cancer	3.26e-05	0.000516	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—testicular cancer	3.25e-05	0.000514	CcSEcCtD
Sorafenib—Nausea—Ifosfamide—testicular cancer	3.22e-05	0.000509	CcSEcCtD
Sorafenib—Diarrhoea—Cisplatin—testicular cancer	3.19e-05	0.000506	CcSEcCtD
Sorafenib—Erythema multiforme—Epirubicin—testicular cancer	3.19e-05	0.000505	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—testicular cancer	3.19e-05	0.000504	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—testicular cancer	3.16e-05	0.0005	CcSEcCtD
Sorafenib—Hypersensitivity—Etoposide—testicular cancer	3.15e-05	0.000499	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—testicular cancer	3.15e-05	0.000498	CcSEcCtD
Sorafenib—Erythema—Methotrexate—testicular cancer	3.14e-05	0.000497	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—testicular cancer	3.14e-05	0.000497	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—testicular cancer	3.14e-05	0.000497	CcSEcCtD
Sorafenib—Flushing—Epirubicin—testicular cancer	3.13e-05	0.000496	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—testicular cancer	3.13e-05	0.000496	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—testicular cancer	3.12e-05	0.000494	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—testicular cancer	3.08e-05	0.000488	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—testicular cancer	3.07e-05	0.000487	CcSEcCtD
Sorafenib—Asthenia—Etoposide—testicular cancer	3.07e-05	0.000486	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—testicular cancer	3.07e-05	0.000486	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—testicular cancer	3.06e-05	0.000485	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—testicular cancer	3.06e-05	0.000484	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—testicular cancer	3.05e-05	0.000482	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—testicular cancer	3.04e-05	0.000481	CcSEcCtD
Sorafenib—Pruritus—Etoposide—testicular cancer	3.03e-05	0.000479	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—testicular cancer	3.01e-05	0.000477	CcSEcCtD
Sorafenib—Alopecia—Epirubicin—testicular cancer	2.98e-05	0.000472	CcSEcCtD
Sorafenib—Vomiting—Cisplatin—testicular cancer	2.97e-05	0.00047	CcSEcCtD
Sorafenib—Mental disorder—Epirubicin—testicular cancer	2.96e-05	0.000468	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—testicular cancer	2.95e-05	0.000467	CcSEcCtD
Sorafenib—Rash—Cisplatin—testicular cancer	2.94e-05	0.000466	CcSEcCtD
Sorafenib—Dermatitis—Cisplatin—testicular cancer	2.94e-05	0.000466	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—testicular cancer	2.94e-05	0.000465	CcSEcCtD
Sorafenib—Erythema—Epirubicin—testicular cancer	2.94e-05	0.000465	CcSEcCtD
Sorafenib—Diarrhoea—Etoposide—testicular cancer	2.93e-05	0.000463	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—testicular cancer	2.91e-05	0.000461	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—testicular cancer	2.9e-05	0.000459	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—testicular cancer	2.9e-05	0.000459	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—testicular cancer	2.9e-05	0.000459	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—testicular cancer	2.88e-05	0.000455	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—testicular cancer	2.83e-05	0.000448	CcSEcCtD
Sorafenib—Dizziness—Etoposide—testicular cancer	2.83e-05	0.000448	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—testicular cancer	2.82e-05	0.000447	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—testicular cancer	2.82e-05	0.000446	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—testicular cancer	2.81e-05	0.000445	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—testicular cancer	2.81e-05	0.000445	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—testicular cancer	2.79e-05	0.000442	CcSEcCtD
Sorafenib—Nausea—Cisplatin—testicular cancer	2.77e-05	0.000439	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—testicular cancer	2.76e-05	0.000437	CcSEcCtD
Sorafenib—Cough—Methotrexate—testicular cancer	2.74e-05	0.000434	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—testicular cancer	2.74e-05	0.000433	CcSEcCtD
Sorafenib—Vomiting—Etoposide—testicular cancer	2.72e-05	0.00043	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—testicular cancer	2.72e-05	0.00043	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—testicular cancer	2.72e-05	0.00043	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—testicular cancer	2.71e-05	0.00043	CcSEcCtD
Sorafenib—ABCB1—lymph node—testicular cancer	2.71e-05	0.000667	CbGeAlD
Sorafenib—Rash—Etoposide—testicular cancer	2.7e-05	0.000427	CcSEcCtD
Sorafenib—Dermatitis—Etoposide—testicular cancer	2.69e-05	0.000426	CcSEcCtD
Sorafenib—Headache—Etoposide—testicular cancer	2.68e-05	0.000424	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—testicular cancer	2.67e-05	0.000423	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—testicular cancer	2.67e-05	0.000423	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—testicular cancer	2.66e-05	0.000421	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	2.65e-05	0.00042	CcSEcCtD
Sorafenib—Syncope—Epirubicin—testicular cancer	2.63e-05	0.000417	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—testicular cancer	2.63e-05	0.000416	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—testicular cancer	2.61e-05	0.000414	CcSEcCtD
Sorafenib—Loss of consciousness—Epirubicin—testicular cancer	2.58e-05	0.000409	CcSEcCtD
Sorafenib—Cough—Epirubicin—testicular cancer	2.56e-05	0.000406	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—testicular cancer	2.56e-05	0.000406	CcSEcCtD
Sorafenib—Infection—Methotrexate—testicular cancer	2.54e-05	0.000403	CcSEcCtD
Sorafenib—Nausea—Etoposide—testicular cancer	2.54e-05	0.000402	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—testicular cancer	2.54e-05	0.000401	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—testicular cancer	2.51e-05	0.000398	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—testicular cancer	2.51e-05	0.000398	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—testicular cancer	2.51e-05	0.000397	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—testicular cancer	2.5e-05	0.000396	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—testicular cancer	2.5e-05	0.000396	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—testicular cancer	2.49e-05	0.000394	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	2.48e-05	0.000393	CcSEcCtD
Sorafenib—Dry mouth—Epirubicin—testicular cancer	2.45e-05	0.000387	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—testicular cancer	2.44e-05	0.000387	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—testicular cancer	2.44e-05	0.000386	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—testicular cancer	2.43e-05	0.000385	CcSEcCtD
Sorafenib—Anaphylactic shock—Epirubicin—testicular cancer	2.4e-05	0.000379	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—testicular cancer	2.39e-05	0.000378	CcSEcCtD
Sorafenib—Infection—Epirubicin—testicular cancer	2.38e-05	0.000377	CcSEcCtD
Sorafenib—Cough—Doxorubicin—testicular cancer	2.37e-05	0.000375	CcSEcCtD
Sorafenib—Shock—Epirubicin—testicular cancer	2.36e-05	0.000373	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—testicular cancer	2.35e-05	0.000372	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—testicular cancer	2.35e-05	0.000372	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—testicular cancer	2.35e-05	0.000371	CcSEcCtD
Sorafenib—RAF1—DAP12 interactions—KIT—testicular cancer	2.34e-05	0.000614	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—KITLG—testicular cancer	2.34e-05	0.000613	CbGpPWpGaD
Sorafenib—Musculoskeletal discomfort—Methotrexate—testicular cancer	2.33e-05	0.000369	CcSEcCtD
Sorafenib—Skin disorder—Epirubicin—testicular cancer	2.33e-05	0.000369	CcSEcCtD
Sorafenib—MAPK11—Signaling by NGF—KIT—testicular cancer	2.33e-05	0.000611	CbGpPWpGaD
Sorafenib—PDGFRB—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	2.33e-05	0.00061	CbGpPWpGaD
Sorafenib—CYP2D6—Biological oxidations—HPGDS—testicular cancer	2.32e-05	0.000609	CbGpPWpGaD
Sorafenib—RAF1—Signaling by EGFR—KIT—testicular cancer	2.32e-05	0.000609	CbGpPWpGaD
Sorafenib—Arthralgia—Doxorubicin—testicular cancer	2.31e-05	0.000366	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—testicular cancer	2.31e-05	0.000366	CcSEcCtD
Sorafenib—BRAF—Signaling by NGF—KIT—testicular cancer	2.31e-05	0.000605	CbGpPWpGaD
Sorafenib—CYP2C9—Biological oxidations—HPGDS—testicular cancer	2.3e-05	0.000604	CbGpPWpGaD
Sorafenib—RAF1—Signaling by EGFR in Cancer—KIT—testicular cancer	2.3e-05	0.000603	CbGpPWpGaD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	2.3e-05	0.000364	CcSEcCtD
Sorafenib—RAF1—Signaling by PDGF—KIT—testicular cancer	2.29e-05	0.000601	CbGpPWpGaD
Sorafenib—KIT—Signaling by NGF—FGFR3—testicular cancer	2.29e-05	0.0006	CbGpPWpGaD
Sorafenib—Anorexia—Epirubicin—testicular cancer	2.29e-05	0.000362	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—testicular cancer	2.28e-05	0.000362	CcSEcCtD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	2.27e-05	0.000594	CbGpPWpGaD
Sorafenib—Dry mouth—Doxorubicin—testicular cancer	2.26e-05	0.000358	CcSEcCtD
Sorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	2.26e-05	0.000593	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—STK11—testicular cancer	2.26e-05	0.000592	CbGpPWpGaD
Sorafenib—Dyspepsia—Methotrexate—testicular cancer	2.25e-05	0.000357	CcSEcCtD
Sorafenib—MAP3K7—Signaling Pathways—INSL3—testicular cancer	2.24e-05	0.000588	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—INSL3—testicular cancer	2.24e-05	0.000588	CbGpPWpGaD
Sorafenib—Decreased appetite—Methotrexate—testicular cancer	2.23e-05	0.000353	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—testicular cancer	2.22e-05	0.000351	CcSEcCtD
Sorafenib—RAF1—Innate Immune System—BCL10—testicular cancer	2.21e-05	0.00058	CbGpPWpGaD
Sorafenib—Gastrointestinal disorder—Methotrexate—testicular cancer	2.21e-05	0.00035	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—testicular cancer	2.21e-05	0.00035	CcSEcCtD
Sorafenib—MKNK1—Disease—H2AFZ—testicular cancer	2.21e-05	0.000579	CbGpPWpGaD
Sorafenib—Infection—Doxorubicin—testicular cancer	2.2e-05	0.000349	CcSEcCtD
Sorafenib—Pain—Methotrexate—testicular cancer	2.19e-05	0.000347	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—testicular cancer	2.18e-05	0.000346	CcSEcCtD
Sorafenib—Shock—Doxorubicin—testicular cancer	2.18e-05	0.000345	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—testicular cancer	2.18e-05	0.000344	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—testicular cancer	2.17e-05	0.000344	CcSEcCtD
Sorafenib—KDR—Axon guidance—MMP2—testicular cancer	2.17e-05	0.000569	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by NGF—FGFR3—testicular cancer	2.17e-05	0.000569	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by NGF—FGFR3—testicular cancer	2.16e-05	0.000568	CbGpPWpGaD
Sorafenib—Skin disorder—Doxorubicin—testicular cancer	2.15e-05	0.000341	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—testicular cancer	2.14e-05	0.000338	CcSEcCtD
Sorafenib—FGFR1—Signaling Pathways—INSL3—testicular cancer	2.13e-05	0.000559	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—INSL3—testicular cancer	2.12e-05	0.000557	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—BCL10—testicular cancer	2.12e-05	0.000557	CbGpPWpGaD
Sorafenib—Anorexia—Doxorubicin—testicular cancer	2.11e-05	0.000335	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—testicular cancer	2.11e-05	0.000334	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—testicular cancer	2.09e-05	0.000332	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—testicular cancer	2.08e-05	0.00033	CcSEcCtD
Sorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	2.07e-05	0.000544	CbGpPWpGaD
Sorafenib—Gastrointestinal disorder—Epirubicin—testicular cancer	2.07e-05	0.000328	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—testicular cancer	2.07e-05	0.000327	CcSEcCtD
Sorafenib—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.06e-05	0.000541	CbGpPWpGaD
Sorafenib—Constipation—Epirubicin—testicular cancer	2.05e-05	0.000325	CcSEcCtD
Sorafenib—Pain—Epirubicin—testicular cancer	2.05e-05	0.000325	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—testicular cancer	2.03e-05	0.000322	CcSEcCtD
Sorafenib—MKNK1—Disease—KITLG—testicular cancer	2.03e-05	0.000533	CbGpPWpGaD
Sorafenib—Body temperature increased—Methotrexate—testicular cancer	2.02e-05	0.000321	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—testicular cancer	2.02e-05	0.000321	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	2.02e-05	0.00032	CcSEcCtD
Sorafenib—FGFR1—Signaling by NGF—KIT—testicular cancer	1.99e-05	0.000523	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by NGF—KIT—testicular cancer	1.99e-05	0.000521	CbGpPWpGaD
Sorafenib—Dyspnoea—Doxorubicin—testicular cancer	1.98e-05	0.000313	CcSEcCtD
Sorafenib—CYP1A2—Biological oxidations—HPGDS—testicular cancer	1.97e-05	0.000516	CbGpPWpGaD
Sorafenib—Gastrointestinal pain—Epirubicin—testicular cancer	1.96e-05	0.00031	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—testicular cancer	1.95e-05	0.000309	CcSEcCtD
Sorafenib—PDGFRB—Signaling by NGF—FGFR3—testicular cancer	1.95e-05	0.000511	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—KITLG—testicular cancer	1.95e-05	0.00051	CbGpPWpGaD
Sorafenib—Decreased appetite—Doxorubicin—testicular cancer	1.93e-05	0.000305	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—testicular cancer	1.91e-05	0.000303	CcSEcCtD
Sorafenib—PDGFRB—Signaling Pathways—INSL3—testicular cancer	1.91e-05	0.000502	CbGpPWpGaD
Sorafenib—Fatigue—Doxorubicin—testicular cancer	1.91e-05	0.000303	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—testicular cancer	1.9e-05	0.000301	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—testicular cancer	1.9e-05	0.0003	CcSEcCtD
Sorafenib—Pain—Doxorubicin—testicular cancer	1.9e-05	0.0003	CcSEcCtD
Sorafenib—RALBP1—Signaling Pathways—H2AFZ—testicular cancer	1.9e-05	0.000497	CbGpPWpGaD
Sorafenib—Abdominal pain—Epirubicin—testicular cancer	1.9e-05	0.0003	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—testicular cancer	1.9e-05	0.0003	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—testicular cancer	1.89e-05	0.000299	CcSEcCtD
Sorafenib—RALBP1—Signaling Pathways—STK11—testicular cancer	1.89e-05	0.000495	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—BCL10—testicular cancer	1.88e-05	0.000493	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—H2AFZ—testicular cancer	1.87e-05	0.000489	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—STK11—testicular cancer	1.86e-05	0.000487	CbGpPWpGaD
Sorafenib—Asthenia—Methotrexate—testicular cancer	1.84e-05	0.000291	CcSEcCtD
Sorafenib—HTR2B—Signaling Pathways—INSL3—testicular cancer	1.82e-05	0.000479	CbGpPWpGaD
Sorafenib—Gastrointestinal pain—Doxorubicin—testicular cancer	1.81e-05	0.000287	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—testicular cancer	1.81e-05	0.000287	CcSEcCtD
Sorafenib—PDGFRB—Signaling by NGF—KIT—testicular cancer	1.79e-05	0.00047	CbGpPWpGaD
Sorafenib—Hypersensitivity—Epirubicin—testicular cancer	1.77e-05	0.00028	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—testicular cancer	1.76e-05	0.000279	CcSEcCtD
Sorafenib—KIT—Innate Immune System—KITLG—testicular cancer	1.75e-05	0.00046	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—KITLG—testicular cancer	1.75e-05	0.00046	CbGpPWpGaD
Sorafenib—Abdominal pain—Doxorubicin—testicular cancer	1.75e-05	0.000278	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—testicular cancer	1.75e-05	0.000278	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—testicular cancer	1.75e-05	0.000277	CcSEcCtD
Sorafenib—RALBP1—Signaling Pathways—KITLG—testicular cancer	1.74e-05	0.000458	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—FGFR3—testicular cancer	1.74e-05	0.000456	CbGpPWpGaD
Sorafenib—Asthenia—Epirubicin—testicular cancer	1.72e-05	0.000272	CcSEcCtD
Sorafenib—FLT4—Signaling Pathways—KITLG—testicular cancer	1.72e-05	0.00045	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—INSL3—testicular cancer	1.71e-05	0.000447	CbGpPWpGaD
Sorafenib—Pruritus—Epirubicin—testicular cancer	1.7e-05	0.000268	CcSEcCtD
Sorafenib—KIT—Immune System—BCL10—testicular cancer	1.69e-05	0.000445	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—BCL10—testicular cancer	1.69e-05	0.000445	CbGpPWpGaD
Sorafenib—Dizziness—Methotrexate—testicular cancer	1.69e-05	0.000268	CcSEcCtD
Sorafenib—KIT—Adaptive Immune System—KITLG—testicular cancer	1.68e-05	0.000442	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—KITLG—testicular cancer	1.68e-05	0.000442	CbGpPWpGaD
Sorafenib—CDK7—Gene Expression—H2AFZ—testicular cancer	1.68e-05	0.000439	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—KITLG—testicular cancer	1.67e-05	0.000437	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—KITLG—testicular cancer	1.66e-05	0.000436	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.65e-05	0.000432	CbGpPWpGaD
Sorafenib—Diarrhoea—Epirubicin—testicular cancer	1.64e-05	0.00026	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—testicular cancer	1.63e-05	0.000259	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—testicular cancer	1.63e-05	0.000258	CcSEcCtD
Sorafenib—Rash—Methotrexate—testicular cancer	1.62e-05	0.000256	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—testicular cancer	1.61e-05	0.000255	CcSEcCtD
Sorafenib—FGFR1—Immune System—BCL10—testicular cancer	1.61e-05	0.000422	CbGpPWpGaD
Sorafenib—Headache—Methotrexate—testicular cancer	1.6e-05	0.000254	CcSEcCtD
Sorafenib—PDGFRA—Immune System—BCL10—testicular cancer	1.6e-05	0.000421	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—KITLG—testicular cancer	1.6e-05	0.000419	CbGpPWpGaD
Sorafenib—FGFR1—Axon guidance—MMP2—testicular cancer	1.6e-05	0.000419	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—KIT—testicular cancer	1.6e-05	0.000418	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—KITLG—testicular cancer	1.59e-05	0.000418	CbGpPWpGaD
Sorafenib—Asthenia—Doxorubicin—testicular cancer	1.59e-05	0.000252	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—testicular cancer	1.59e-05	0.000251	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—testicular cancer	1.57e-05	0.000248	CcSEcCtD
Sorafenib—CDK7—Disease—H2AFZ—testicular cancer	1.56e-05	0.000408	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—MMP2—testicular cancer	1.55e-05	0.000406	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—H2AFZ—testicular cancer	1.55e-05	0.000406	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—STK11—testicular cancer	1.54e-05	0.000403	CbGpPWpGaD
Sorafenib—Vomiting—Epirubicin—testicular cancer	1.52e-05	0.000241	CcSEcCtD
Sorafenib—Nausea—Methotrexate—testicular cancer	1.52e-05	0.000241	CcSEcCtD
Sorafenib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	1.52e-05	0.000398	CbGpPWpGaD
Sorafenib—Diarrhoea—Doxorubicin—testicular cancer	1.52e-05	0.00024	CcSEcCtD
Sorafenib—Rash—Epirubicin—testicular cancer	1.51e-05	0.000239	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—testicular cancer	1.51e-05	0.000239	CcSEcCtD
Sorafenib—MKNK1—Disease—FGFR3—testicular cancer	1.51e-05	0.000396	CbGpPWpGaD
Sorafenib—Headache—Epirubicin—testicular cancer	1.5e-05	0.000238	CcSEcCtD
Sorafenib—PDGFRB—Innate Immune System—KITLG—testicular cancer	1.5e-05	0.000392	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—INSL3—testicular cancer	1.47e-05	0.000386	CbGpPWpGaD
Sorafenib—Dizziness—Doxorubicin—testicular cancer	1.47e-05	0.000232	CcSEcCtD
Sorafenib—MAPK11—Innate Immune System—FGFR3—testicular cancer	1.45e-05	0.000379	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—BCL10—testicular cancer	1.45e-05	0.000379	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—KITLG—testicular cancer	1.44e-05	0.000377	CbGpPWpGaD
Sorafenib—CDK7—Disease—KITLG—testicular cancer	1.43e-05	0.000375	CbGpPWpGaD
Sorafenib—Nausea—Epirubicin—testicular cancer	1.42e-05	0.000225	CcSEcCtD
Sorafenib—MKNK1—Signaling Pathways—KITLG—testicular cancer	1.42e-05	0.000373	CbGpPWpGaD
Sorafenib—Vomiting—Doxorubicin—testicular cancer	1.41e-05	0.000223	CcSEcCtD
Sorafenib—Rash—Doxorubicin—testicular cancer	1.4e-05	0.000221	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—testicular cancer	1.4e-05	0.000221	CcSEcCtD
Sorafenib—FLT1—Signaling Pathways—H2AFZ—testicular cancer	1.39e-05	0.000365	CbGpPWpGaD
Sorafenib—Headache—Doxorubicin—testicular cancer	1.39e-05	0.00022	CcSEcCtD
Sorafenib—MKNK1—Disease—KIT—testicular cancer	1.39e-05	0.000364	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—STK11—testicular cancer	1.38e-05	0.000363	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—KITLG—testicular cancer	1.33e-05	0.00035	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—MMP2—testicular cancer	1.33e-05	0.000349	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—KIT—testicular cancer	1.33e-05	0.000348	CbGpPWpGaD
Sorafenib—Nausea—Doxorubicin—testicular cancer	1.32e-05	0.000209	CcSEcCtD
Sorafenib—KIT—Innate Immune System—FGFR3—testicular cancer	1.3e-05	0.000342	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—FGFR3—testicular cancer	1.3e-05	0.000342	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—FGFR3—testicular cancer	1.3e-05	0.00034	CbGpPWpGaD
Sorafenib—RAF1—Immune System—BCL10—testicular cancer	1.29e-05	0.000338	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—KITLG—testicular cancer	1.28e-05	0.000336	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—KITLG—testicular cancer	1.28e-05	0.000336	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—MMP2—testicular cancer	1.28e-05	0.000336	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—FGFR3—testicular cancer	1.28e-05	0.000335	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—FGFR3—testicular cancer	1.25e-05	0.000328	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—FGFR3—testicular cancer	1.25e-05	0.000328	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—FGFR3—testicular cancer	1.24e-05	0.000325	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—FGFR3—testicular cancer	1.23e-05	0.000324	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—H2AFZ—testicular cancer	1.22e-05	0.000321	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—KIT—testicular cancer	1.2e-05	0.000314	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—KIT—testicular cancer	1.19e-05	0.000312	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—FGFR3—testicular cancer	1.19e-05	0.000312	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—FGFR3—testicular cancer	1.19e-05	0.000311	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—KIT—testicular cancer	1.17e-05	0.000307	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—KIT—testicular cancer	1.15e-05	0.000302	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—MMP2—testicular cancer	1.14e-05	0.000299	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—KIT—testicular cancer	1.14e-05	0.000298	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—KITLG—testicular cancer	1.13e-05	0.000297	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—KIT—testicular cancer	1.13e-05	0.000297	CbGpPWpGaD
Sorafenib—BRAF—Disease—H2AFZ—testicular cancer	1.13e-05	0.000296	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—FGFR3—testicular cancer	1.11e-05	0.000292	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—KIT—testicular cancer	1.09e-05	0.000286	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—KIT—testicular cancer	1.09e-05	0.000285	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.09e-05	0.000285	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—FGFR3—testicular cancer	1.07e-05	0.00028	CbGpPWpGaD
Sorafenib—CDK7—Disease—FGFR3—testicular cancer	1.06e-05	0.000279	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—FGFR3—testicular cancer	1.06e-05	0.000277	CbGpPWpGaD
Sorafenib—BRAF—Disease—KITLG—testicular cancer	1.04e-05	0.000272	CbGpPWpGaD
Sorafenib—KIT—Disease—H2AFZ—testicular cancer	1.03e-05	0.000269	CbGpPWpGaD
Sorafenib—KIT—Immune System—KITLG—testicular cancer	1.02e-05	0.000268	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—KITLG—testicular cancer	1.02e-05	0.000268	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—KIT—testicular cancer	1.02e-05	0.000268	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—FGFR3—testicular cancer	9.91e-06	0.00026	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—KIT—testicular cancer	9.8e-06	0.000257	CbGpPWpGaD
Sorafenib—CDK7—Disease—KIT—testicular cancer	9.76e-06	0.000256	CbGpPWpGaD
Sorafenib—FGFR1—Disease—H2AFZ—testicular cancer	9.73e-06	0.000255	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—H2AFZ—testicular cancer	9.71e-06	0.000255	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—KIT—testicular cancer	9.71e-06	0.000255	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—KITLG—testicular cancer	9.7e-06	0.000254	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.69e-06	0.000254	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—KITLG—testicular cancer	9.67e-06	0.000254	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—FGFR3—testicular cancer	9.52e-06	0.00025	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—FGFR3—testicular cancer	9.52e-06	0.00025	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—H2AFZ—testicular cancer	9.5e-06	0.000249	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—STK11—testicular cancer	9.45e-06	0.000248	CbGpPWpGaD
Sorafenib—KIT—Disease—KITLG—testicular cancer	9.43e-06	0.000247	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—H2AFZ—testicular cancer	9.26e-06	0.000243	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—STK11—testicular cancer	9.21e-06	0.000242	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—HPGDS—testicular cancer	9.18e-06	0.000241	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—HPGDS—testicular cancer	9.18e-06	0.000241	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—MMP2—testicular cancer	9.13e-06	0.000239	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—KIT—testicular cancer	9.1e-06	0.000239	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KITLG—testicular cancer	8.95e-06	0.000235	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KITLG—testicular cancer	8.93e-06	0.000234	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	8.84e-06	0.000232	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—H2AFZ—testicular cancer	8.75e-06	0.000229	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KITLG—testicular cancer	8.74e-06	0.000229	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—KIT—testicular cancer	8.74e-06	0.000229	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—KIT—testicular cancer	8.74e-06	0.000229	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KITLG—testicular cancer	8.71e-06	0.000229	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KITLG—testicular cancer	8.52e-06	0.000224	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—FGFR3—testicular cancer	8.42e-06	0.000221	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KITLG—testicular cancer	8.05e-06	0.000211	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—H2AFZ—testicular cancer	7.96e-06	0.000209	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—STK11—testicular cancer	7.92e-06	0.000208	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—H2AFZ—testicular cancer	7.89e-06	0.000207	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—STK11—testicular cancer	7.84e-06	0.000206	CbGpPWpGaD
Sorafenib—RAF1—Disease—H2AFZ—testicular cancer	7.8e-06	0.000204	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—HPGDS—testicular cancer	7.79e-06	0.000204	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KITLG—testicular cancer	7.77e-06	0.000204	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—KIT—testicular cancer	7.73e-06	0.000203	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—HPGDS—testicular cancer	7.72e-06	0.000203	CbGpPWpGaD
Sorafenib—BRAF—Disease—FGFR3—testicular cancer	7.7e-06	0.000202	CbGpPWpGaD
Sorafenib—KIT—Immune System—FGFR3—testicular cancer	7.59e-06	0.000199	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—FGFR3—testicular cancer	7.59e-06	0.000199	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.55e-06	0.000198	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KITLG—testicular cancer	7.33e-06	0.000192	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KITLG—testicular cancer	7.26e-06	0.00019	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—FGFR3—testicular cancer	7.21e-06	0.000189	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—FGFR3—testicular cancer	7.19e-06	0.000189	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—H2AFZ—testicular cancer	7.18e-06	0.000188	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—H2AFZ—testicular cancer	7.18e-06	0.000188	CbGpPWpGaD
Sorafenib—RAF1—Disease—KITLG—testicular cancer	7.17e-06	0.000188	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—STK11—testicular cancer	7.14e-06	0.000187	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—STK11—testicular cancer	7.14e-06	0.000187	CbGpPWpGaD
Sorafenib—BRAF—Disease—KIT—testicular cancer	7.07e-06	0.000186	CbGpPWpGaD
Sorafenib—KIT—Disease—FGFR3—testicular cancer	7.01e-06	0.000184	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—KIT—testicular cancer	6.97e-06	0.000183	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—H2AFZ—testicular cancer	6.82e-06	0.000179	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—H2AFZ—testicular cancer	6.8e-06	0.000178	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—STK11—testicular cancer	6.78e-06	0.000178	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STK11—testicular cancer	6.76e-06	0.000177	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—STK11—testicular cancer	6.67e-06	0.000175	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—STK11—testicular cancer	6.67e-06	0.000175	CbGpPWpGaD
Sorafenib—FGFR1—Disease—FGFR3—testicular cancer	6.65e-06	0.000175	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—FGFR3—testicular cancer	6.64e-06	0.000174	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—KIT—testicular cancer	6.62e-06	0.000174	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KITLG—testicular cancer	6.61e-06	0.000173	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KITLG—testicular cancer	6.61e-06	0.000173	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—KIT—testicular cancer	6.6e-06	0.000173	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—FGFR3—testicular cancer	6.5e-06	0.00017	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—FGFR3—testicular cancer	6.48e-06	0.00017	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FGFR3—testicular cancer	6.33e-06	0.000166	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KITLG—testicular cancer	6.27e-06	0.000164	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KITLG—testicular cancer	6.25e-06	0.000164	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—H2AFZ—testicular cancer	6.12e-06	0.000161	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KIT—testicular cancer	6.11e-06	0.00016	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KIT—testicular cancer	6.09e-06	0.00016	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STK11—testicular cancer	6.09e-06	0.00016	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—FGFR3—testicular cancer	5.98e-06	0.000157	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KIT—testicular cancer	5.97e-06	0.000156	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KIT—testicular cancer	5.95e-06	0.000156	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—H2AFZ—testicular cancer	5.84e-06	0.000153	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KIT—testicular cancer	5.81e-06	0.000153	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STK11—testicular cancer	5.81e-06	0.000152	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FGFR3—testicular cancer	5.77e-06	0.000151	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—HPGDS—testicular cancer	5.71e-06	0.00015	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—STK11—testicular cancer	5.66e-06	0.000149	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KITLG—testicular cancer	5.63e-06	0.000148	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—STK11—testicular cancer	5.61e-06	0.000147	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—HPGDS—testicular cancer	5.58e-06	0.000146	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KIT—testicular cancer	5.49e-06	0.000144	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—H2AFZ—testicular cancer	5.46e-06	0.000143	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FGFR3—testicular cancer	5.45e-06	0.000143	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STK11—testicular cancer	5.43e-06	0.000142	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FGFR3—testicular cancer	5.39e-06	0.000142	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KITLG—testicular cancer	5.37e-06	0.000141	CbGpPWpGaD
Sorafenib—RAF1—Disease—FGFR3—testicular cancer	5.33e-06	0.00014	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KIT—testicular cancer	5.3e-06	0.000139	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KITLG—testicular cancer	5.02e-06	0.000132	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KIT—testicular cancer	5e-06	0.000131	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KIT—testicular cancer	4.95e-06	0.00013	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGFR3—testicular cancer	4.91e-06	0.000129	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGFR3—testicular cancer	4.91e-06	0.000129	CbGpPWpGaD
Sorafenib—RAF1—Disease—KIT—testicular cancer	4.89e-06	0.000128	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—HPGDS—testicular cancer	4.84e-06	0.000127	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—H2AFZ—testicular cancer	4.71e-06	0.000124	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STK11—testicular cancer	4.69e-06	0.000123	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGFR3—testicular cancer	4.66e-06	0.000122	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGFR3—testicular cancer	4.65e-06	0.000122	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KIT—testicular cancer	4.51e-06	0.000118	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KITLG—testicular cancer	4.34e-06	0.000114	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—HPGDS—testicular cancer	4.32e-06	0.000113	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KIT—testicular cancer	4.28e-06	0.000112	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KIT—testicular cancer	4.27e-06	0.000112	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—HPGDS—testicular cancer	4.21e-06	0.000111	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGFR3—testicular cancer	4.19e-06	0.00011	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—STK11—testicular cancer	4.15e-06	0.000109	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—STK11—testicular cancer	4.06e-06	0.000106	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGFR3—testicular cancer	3.99e-06	0.000105	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—HPGDS—testicular cancer	3.97e-06	0.000104	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HPGDS—testicular cancer	3.94e-06	0.000103	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KIT—testicular cancer	3.84e-06	0.000101	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGFR3—testicular cancer	3.73e-06	9.79e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KIT—testicular cancer	3.67e-06	9.62e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—STK11—testicular cancer	3.51e-06	9.22e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KIT—testicular cancer	3.43e-06	8.99e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HPGDS—testicular cancer	3.36e-06	8.82e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGFR3—testicular cancer	3.22e-06	8.45e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—STK11—testicular cancer	3.14e-06	8.23e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—STK11—testicular cancer	3.06e-06	8.03e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KIT—testicular cancer	2.96e-06	7.76e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—STK11—testicular cancer	2.88e-06	7.57e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—STK11—testicular cancer	2.86e-06	7.5e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HPGDS—testicular cancer	2.6e-06	6.81e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—STK11—testicular cancer	2.44e-06	6.41e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—STK11—testicular cancer	1.89e-06	4.95e-05	CbGpPWpGaD
